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Abstract
Introduction: A reliable diagnostic biomarker of iron status is required for severely anemic children living in malarious areas
because presumptive treatment with iron may increase their infection risk if they are not iron deficient. Current biomarkers
are limited because they are altered by host inflammation. In this study hepcidin concentrations were assessed in severely
anemic children living in a highly malarious area of Malawi and evaluated against bone marrow iron in order to determine
the usefulness of hepcidin as a point of care test.
Methods: 207 severely anemic children were assessed for levels of hepcidin, ferritin, serum transferrin receptor,
erythropoietin, hematological indices, C-reactive protein, interleukin-6, malaria parasites and HIV infection. Deficiency of
bone marrow iron stores was graded and erythroblast iron incorporation estimated. Interaction of covariates was assessed
by structural-equation-modeling.
Results and Conclusion: Hepcidin was a poor predictor of bone marrow iron deficiency (sensitivity 66.7%; specificity 48.5%),
and of iron incorporation (sensitivity 54.2%; specificity 61.8%), and therefore would have limitations as a point of care test in
this category of children. As upregulation of hepcidin by inflammation and iron status was blunted by erythropoietin in this
population, enhanced iron absorption through the low hepcidin values may increase infection risk. Current
recommendations to treat all severely anemic children living in malarious areas with iron should therefore be reconsidered.
Citation: Jonker FAM, Calis JCJ, Phiri K, Kraaijenhagen RJ, Brabin BJ, et al. (2013) Low Hepcidin Levels in Severely Anemic Malawian Children with High Incidence
of Infectious Diseases and Bone Marrow Iron Deficiency. PLoS ONE 8(12): e78964. doi:10.1371/journal.pone.0078964
Editor: Ann M. Moormann, University of Massachusetts Medical School, United States of America
Received August 2, 2013; Accepted September 17, 2013; Published December 5, 2013
Copyright:  2013 Jonker et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a grant (064722) from the Wellcome Trust and by independent grants from the Nutricia Research Foundation, Stichting
Emma Steun, and JANIVO Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: D.W.S and H.T are medical director and managing director, respectively, of the www.hepcidinanalysis.com initiative that serves the
scientific and medical community with hepcidin measurements at a fee-for service basis. The remaining authors declare no competing financial interests. This
does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: femkje.jonker@gmail.com
Introduction
Iron deficiency is a nutritional disorder highly prevalent among
pre-school children living in developing countries [1] and as a
major contributor to child morbidity [2,3], iron supplementation
programs have been prioritized [4]. In view of concerns that iron
supplementation may increase malaria related morbidity and
mortality, especially in iron replete children, [5,6], the World
Health Organization (WHO) recommended diagnosis of iron
deficiency prior to supplementation [6].This recommendation is
problematic in malarious areas as a reliable bio-marker to identify
iron deficiency is not available due to the effects of inflammation
on biomarker concentrations. The WHO also advises iron
treatment of children with signs of severe anemia [6]. Yet a large
proportion of severely anemic children living in highly malarious
areas may be iron replete [7] and iron presumptive treatment may
enhance their infection risk. A peripheral blood iron biomarker for
reliable iron status assessment is required to ensure safety of
preventive and curative iron interventions.
The iron regulator hepcidin [8–10] plays a central role in the
interaction between iron deficiency, anemia and inflammation
[11–13]. In iron loaded conditions and during inflammation/
infection increased hepcidin levels cause a decrease in intestinal
iron absorption, and iron release from storage through degrada-
tion of the cellular iron exporter ferroportin. [11,12,14,15].
Conversely, iron deficiency, hypoxia and enhanced erythropoiesis
decrease hepcidin levels, [12,14,16] leading to an increase in iron
levels. In view of its central role in iron homeostasis serum
hepcidin could be a useful marker to guide iron supplementation
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interventions, even in areas with high infection exposure [17–19],
although it has yet to be evaluated for this purpose [20]. In this
study we evaluated serum hepcidin as a predictor of deficient bone
marrow iron stores, and erythroblast iron incorporation in severely
anemic Malawian children. Impact on serum hepcidin of iron
levels, inflammation, hypoxia and erythropoiesis was also assessed.
Patients and Methods
Study design and population
This study formed part of a large research program conducted
between 2002–2004 investigating the etiology, pathogenesis and
outcome of severe anemia in Malawian children. A detailed
description of the study methodology is available [7,21]. In brief,
381 children (6–60 months old) presenting with severe anemia
(hemoglobin,5.0 g per deciliter) were enrolled as ‘cases’ if they
had not been transfused in the previous 4 weeks. For each case,
two controls were enrolled, a community-control living within
100–1000 meters of the case, and a hospital-control, presenting at
the same hospital or outpatient facility as the case. Controls were
eligible for recruitment if they were aged between 6–60 months
and if their hemoglobin level was 5.0 gram per deciliter or more.
At recruitment a venous blood sample was obtained and, (in cases)
if the clinical condition allowed, a bone marrow aspiration was
performed.
For the hepcidin study, all cases with available bone marrow
aspirates were included. In order to compare hepcidin levels
between severely anemic and non-severely anemic children,
hepcidin was also assessed in a sub-sample of controls (without
available bone marrow aspirates). Of the 757 controls, 43 children
were randomly selected for hepcidin assessment. Hematological
status of this sub-group was comparable to all controls (data not
shown).
Written informed consent was obtained from a parent or
guardian of each child. The study was approved by the Ethics
Committees of the College of Medicine, Malawi, and the
Liverpool School of Tropical Medicine, United Kingdom.
Laboratory investigations
Hemoglobin, mean cellular volume (MCV) and mean corpus-
cular hemoglobin concentration (MCHC) were measured by a
Coulter counter analyzer (Beckman Coulter, Durban, South
Africa). Bone marrow slides were stained with Hematognost Fe
(Merck, Darmstadt, Germany) and graded for intracellular iron
content using a histological grading method which classifies iron
status into six grades (0–6) [22]. In addition, all marrow smears
were also assessed using an alternative grading method where
utilizable iron was specifically assessed through determination of
iron in the erythroblasts. At high power magnification (*1000) 20
fields surrounding the marrow fragments were examined and a
hundred erythroblasts were examined to enumerate the percent-
age containing iron granules in their cytoplasm [23].
Within the first hour after collection, heparin plasma and serum
aliquots were stored at 280uC. These samples were used for later
(2009) assessment of hepcidin-25 (the bioactive, active form of the
peptide). As outcome of assessments of plasma and serum hepcidin
is comparable we will refer to concentrations as serum hepcidin.
Hepcidin assessments were measured by a combination of weak
cation exchange chromatography and time-of-flight mass spec-
trometry (WCX-TOF-MS) [24]. An internal standard (synthetic
hepcidin-24; Peptide International Inc., Louisville, KY) was used
for quantification [25]. Peptide spectra were generated on a
Microflex LT matrix-enhanced laser desorption/ionization
(MALDI) TOF-MS platform (Bruker Daltonics, Bremen, Ger-
many). Serum hepcidin-25 concentrations are expressed as
nanomoles per liter (nmol/L). The lower limit of detection of this
method was 0.5 nmol/L [24]. Samples found to have a hepcidin
concentration ,0.5 nmol/L (57%) were imputed with a random
value out of a uniform distribution with a minimum of 0.01 nmol/
L and a maximum of 0.5 nmol/L. Ferritin was determined using
electro-chemiluminescence immunoassay (Modular Analytics
E170, Roche Diagnostics, Switzerland). Erythropoietin was
determined using Immulite 2000 (maximum detection limit
,200 and after dilution .1000 IU/L; Siemens DPC, New Jersey,
USA). (Immunoturbidimetric assay (Modular P800, Roche Diag-
nostics, Switzerland) was used to determine serum transferrin and
C-reactive protein (CRP). Soluble transferrin receptor (sTfR) was
measured using an enzyme immunoassay (Ramco Laboratories,
TX, USA, detection limit 1.0 mg/l). Interleukin-6 (IL-6) was
measured by Cytometric Bead Array on a FACS- Calibur flow-
cytometer (Becton-Dickson, South Africa). Clinical malaria was
defined as a positive blood slide with concurrent fever (axillary
temp .37.5uC), or history of fever within the previous 48 hours.
Definitions
Deficiency of bone marrow iron stores was defined as grade 0 or
1 [22,26]. Erythroblast iron incorporation was used as a proxy for
utilizable iron in the bone marrow; insufficient erythroblast iron
incorporation (functional bone marrow iron deficiency) was
defined as less than 30% of the erythroblasts having visible iron
granules while having replete iron stores [23]. Cut-off values for
iron deficiency of the peripheral iron markers were as follows:
hepcidin,0.5 nmol/L [27]; ferritin,30 mg/L [28];
sTfR.8.3 mg/ml; MCHC,32 g/L [3]; MCV,67 fl (,2 years
old) and ,73 fl (2–5 years old) [3]. Soluble transferrin log-ferritin
index (sTfR-F index) was defined as [sTfR 4 log ferritin] in which
log refers to ‘base-10 log’ [29]. Using the cut-offs sTfR.8.3 mg/L
and ferritin,30 mg/L, a cut-off for sTfR-F index was calculated
(.5.6).
Statistical Methods
Data were analyzed with use of SPSS 20.0 and AMOS 20.0
statistical computer packages (SPSS, Chicago, Illinois). Correla-
tions with bone marrow iron gradings were assessed with the
Kendall rank correlation test for ordinal data. Median hepcidin
levels between the different sub-groups were compared using the
Mann-Whitney U test. Using the dichotomous outcome of bone
marrow iron status and erythroblast iron incorporation, receiver
operating characteristics (ROC) curves and corresponding areas
under the curve (AUCROC) were created for hepcidin and
conventional iron markers. The ROC curves were used to assess
a cut-off for hepcidin providing optimal sensitivity and specificity
in predicting bone marrow iron deficiency, and for all iron makers
in predicting insufficient erythroblast iron incorporation.
To evaluate different signaling pathways of hepcidin, all
relevant available covariates relating to hepcidin were analyzed
using linear regression models with bone marrow iron deficiency
as outcome. These predictors of hepcidin included erythropoietin
and reticulocytosis (erythropoiesis), hemoglobin (hypoxia), bone
marrow iron grading (iron status), CRP, IL-6, malaria and
bacteremia (inflammation). Multivariate linear regression was
performed with a model predicting log-hepcidin including one
proxy variable for each pathway (bone marrow iron status, CRP,
hemoglobin and erythropoietin).
To evaluate the association between hepcidin and erythroblast
iron incorporation, all relevant available covariates relating to
erythroblast iron incorporation (hepcidin, use of hematinics in the
Hepcidin in Severely Anemic Children
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previous 4 weeks and CRP) were analyzed using univariate and
multivariate logistic regression.
Missing observations were included in analyses by creating
missing-value categories. Reported p-values are two-sided; statis-
tical significance was set at the conventional 5% level.
Structural equation model. More complex multivariate
analyses allowing interaction of covariates were performed using
structural equation modeling [30]. This model was created
containing all possible associations between all relevant available
variables relating to hepcidin, plus malaria and bacteremia.
Associations are indicated by standardized regression coefficients.
All non-significant associations (p$0.05) were removed. Relevant
non-significant coefficients were retained and are displayed as
dashed arrows. C-reactive protein was adjusted for malaria and
bacteremia; interleukin 6 was adjusted for bacteremia. Skewed
variables were log-transformed. Missing observations were con-
sidered as missing at random and were imputed by single
imputation [30].
Table 1. Baseline characteristics of the study population.
Characteristic severely anemic cases
non-severely anemic
controls
Demographics N 207 43
Male 48.8% (101/207) 69.8% (30/43)
Age (months) 14.0 (9.7–26.3) 20.1 (10.6–28.3)
Hematological status Hemoglobin (g/dl) 3.6 (0.8) 9.7 (1.9)
MCHC (g/dl) 32.60(6.8) 33.2 (5.4)
MCV (fl) 82.7 (15.4) 71.2 (8.0)
Reticulocytes % 3.6 (2.1–6.7) 2.3 (1.7–4.3)
Erythropoietin .1000 U/L 95.6% (108/113) 0% (0/39)
Iron status Deficiency of bone marrow iron stores 30.2% (42/139) n/a
Insufficient erythroblast iron incorporation 41.4% (48/116) n/a
Hepcidin (nmol/L) 0.40 (0.19–2.10) 1.40 (0.31–5.60)
Ferritin (mg/l) 404 (157–905) 50 (12–171)
sTfR (mg/ml) 13.4 (8.1–22.4) 12.5 (7.2–17.5)
sTfR-F index 5.1 (3.1–9.6) 5.9 (3.1–12.0)
Inflammatory status Bacteremia 12.6% (25/198) 0% (0/20)
Malaria 59.9% (124/207) 37.2% (16/43)
HIV infected 7.7% (15/195) 3.7% (2/43)
CRP.40 mg/L 81.2% (159/196) 37.7% (12/31)
Interleukin-6 pg/ml 41.6 (20.9–142.3) 25.6 (10.0–67.3
Deficiency of bone marrow iron stores was defined as a bone marrow iron score of 0 or 1; Deficiency of functional bone marrow iron was defined as,30% iron deficient
erythroblasts while having replete iron stores [22,26]; CRP: C-Reactive Protein; HIV: Human Immunodeficiency Virus; MCHC: mean cell hemoglobin concentration; MCV
mean corpuscular volume; sTfR: soluble transferrin receptor; sTfR-F index: sTfR-log ferritin index31Normally distributed variables are presented with their mean value
(s.d.); skewed variable are presented with their median value (inter quartile range). Malaria was defined as a positive blood slide with concurrent fever (axillary temp
.37.5uC), or history of fever within the previous 48 hours.
doi:10.1371/journal.pone.0078964.t001
Table 2. Performance of biochemical iron markers to identify children with deficiency of bone marrow iron stores or insufficient
erythroblast iron incorporation.
Bone marrow iron deficiency Insufficient erythroblast iron incorporation
Iron marker AUCROC p value
Sensitivity
(%) 95% CI
Specificity
(%) 95% CI AUCROC p value
Sensitivity
(%) 95% CI
Specificity
(%) 95% CI
Hepcidin (nmol/L)0.598 0.07 66.7 50,5 80,4 49.5 39,2 59,8 0.591 0.1 54.2 39,2 68,6 61.8 49,2 73,3
Ferritin (ug/l) 0.855 ,00001 41.7 22,2 63,3 98.1 87,7 99,7 0.524 0.8 48.0 28,7 68,0 54.1 36,9 70,5
sTfR (ug/ml) 0.823 ,00001 92.5 79,6 98,4 35.5 25,8 46,1 0.634 0.02 58.7 43,2 73,0 57.6 44,8 69,7
sTfR-F index 0.815 ,00001 75.0 53,3 90,2 73.5 58,9 85,0 0.577 0.3 96.2 80,3 99,4 13.9 4,7 29,5
MCHC (g/dl) 0.727 ,00001 61.5 46,5 80,2 68.4 57,9 78,9 0.447 0.4 45.0 29,3 61,5 50.9 37,1 64,6
MCV (fl) 0.489 0.9 22.9 10,5 40,1 90.1 81,5 95,6 0.676 0.003 70.0 53,5 83,4 58.9 45,0 71,9
Deficiency of bone marrow iron stores was defined as a bone marrow iron score of 0 or 1; CRP: C-Reactive Protein; HIV: Human Immunodeficiency Virus; MCHC: mean
cell hemoglobin concentration; MCV mean corpuscular volume; sTfR: soluble transferrin receptor; sTfR-F index: sTfR-log ferritin index. Insufficient erythroblast iron
incorporation: defined as ,30% iron deficient erythroblasts. AUC area under the curve; ROC: receiver operating characteristics.
doi:10.1371/journal.pone.0078964.t002
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Results
Of the 381 severely anemic children enrolled in the study, 237
underwent a bone marrow aspirate. In 139 of these children a
serum sample with sufficient volume for hepcidin assessment was
available. Hematological status of children with or without
hepcidin and/or bone marrow assessment was comparable (data
not shown). In Table 1 baseline characteristics of the severely
anemic study group and the non-severely anemic control group
are presented. Bone marrow iron deficiency, inflammation
(CRP.40.0 mg/L) and high levels of erythropoietin
(epo.1000 u/L), were found in 30.2%, 81.2% and 95.6% of
severely anemic children, respectively. The median value of
hepcidin in the severely anemic children was 0.40 nmol/L (IQR
0.19–2.10 nmol/L), and 1.40 nmol/L (0.31–5.60 nmol/L) in the
non-severely anemic control group (p = 0.04).
Hepcidin predicting bone marrow iron status and
erythroblast iron incorporation
Hepcidin levels poorly correlated with bone marrow iron
grading (Kendall rank correlation coefficient 0.05, p = 0.5). The
ROC-curve for hepcidin identifying bone marrow iron deficiency
showed an area under curve (AUCROC) of 0.598, marginally
higher than 0.500 (p = 0.07), the cut-off to indicate an effective test.
The optimal cut-off for hepcidin to predict bone marrow iron
deficiency, derived from the ROC-curve, was 0.5 nmol/L. Using
this cut-off, hepcidin sensitivity and specificity estimates to detect
bone marrow iron deficiency were 66.7% and 49.5% respectively.
The AUCROC, sensitivity and specificity of ferritin, sTfR, sTfR-F
index and MCV and MCHC were additionally assessed and are
shown in table 2.
Of the 139 available bone marrow smears, 23 were excluded
from the erythroblast iron incorporation analyses because of poor
Figure 1. Univariate and multivariate logistic regression analyses with all relevant covariates predicting erythroblast iron
incorporation. Regression coefficients are presented with their 95% confidence intervals. Insufficient erythroblast iron incorporation was defined as
less than 30% erythroblasts having visible iron granules while having replete iron stores [23]. CRP: c-reactive protein. Previous use of hematinics is
defined as use of iron supplements in the previous four weeks.
doi:10.1371/journal.pone.0078964.g001
Figure 2. Univariate and multivariate linear regression analyses with all relevant covariates predicting log hepcidin. Regression
coefficients are presented with 95% confidence interval. Bone marrow iron stores was scores in a range from 0 to 6 [22]. CRP: c-reactive protein; IL-6:
interleukin 6. Bacteremia was analyzed as dichotomous variable. Malaria was defined as a positive blood slide with concurrent fever (axillary temp
.37.5uC), or history of fever within the previous 48 hours.
doi:10.1371/journal.pone.0078964.g002
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staining. Of the remaining samples, 49 (41.4%) showed insufficient
erythroblast iron incorporation. The assessments of hepcidin and
conventional iron markers to predict erythroblast iron incorpora-
tion are shown in table 2. The AUCROC for hepcidin was 0.591
(p = 0.1). Using the optimal cut-off of 0.5 nmol/L, sensitivity and
specificity of hepcidin to predict insufficient erythroblast iron
incorporation were 54.2% and 61.8%, respectively (Table 2). The
univariate and multivariate logistic regression analyses to model
the relation between hepcidin and erythroblast iron incorporation
are shown in figure 1. Applying these variables in the structural
equation model (figure 2) it was found that CRP, but not hepcidin
levels, were positively associated with insufficient erythroblast iron
incorporation (regression coefficient of 0.13, p = 0.02, and 20.03,
p = 0.6 for CRP and hepcidin, respectively). The overall root mean
square area of approximation, an indicator for model fit, was
0.288 (95% CI 0.272–0.304). Exclusion of non-significant
associations gave a virtually identical model’
The prioritizing of the four hepcidin signaling pathways
Univariate and multivariate associations of the available
variables belonging to the four signaling pathways [12] of hepcidin
are illustrated in figure 3. The iron pathway, represented by bone
marrow iron stores had a weak association with hepcidin
(regression coefficient 0.05, p = 0.6). The inflammation pathway,
represented by CRP and IL-6, was strongly positively associated
with hepcidin (regression coefficients of 0.29, p,0.0001 and 0.46,
p,0.0001 respectively). CRP was adjusted for malaria and
bacteremia; IL-6 was adjusted for bacteremia. The hypoxia pathway
reflected by hemoglobin concentration was not associated with
hepcidin (regression coefficient +0.03, p = 0.7). For the erythropoietic
pathway, erythropoietin had a strong negative association with
hepcidin (regression coefficient 20.81, p,0.0001). The overall
root mean square area of approximation, an indicator for model
fit, was 0.288 (95% CI 0.272–0.304). Exclusion of non-significant
associations gave a virtually identical model’
Figure 3. Structural equation model for hepcidin, hypoxia/erythropoiesis, iron status and inflammation. In this exploratory model of
the factors associated with serum hepcidin, the sizes of the associations are indicated by the standardized regression coefficients. An inverse
association is indicated by a red line. This model was created containing all possible associations between the displayed variables, after which all non-
significant arrows (p$0.05) were removed. A few non-significant correlations, deemed relevant by the authors, were retained in the figure, displayed
as dashed arrows. C-reactive protein (CRP) was adjusted for malaria and bacteremia; interleukin 6 (IL-6) was adjusted for bacteremia (omitted for
clarity). Iron in stores was defined as bone marrow iron score (0–6) [22]. Insufficient erythrocyte iron incorporation was defined as less than 30%
erythroblasts having visible iron granules while having replete iron stores. Erythroblast iron was defined as more than 30% of the erythroblasts having
visible iron granules while having replete bone marrow iron stores [23]. The overall root mean square area of approximation, an indicator for model
fit, was 0.288 (95% CI 0.272–0.304).
doi:10.1371/journal.pone.0078964.g003
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Discussion
This is the first study evaluating hepcidin and bone marrow iron
status in severely anemic African children. Hepcidin levels were
largely undetectable, probably as a result of a dominance of the
erythropoietin signal for hepcidin. As a consequence, hepcidin
poorly correlated with the iron pathway and was therefore not a
good marker for iron deficiency. Furthermore, it was found that
hepcidin was also not associated with the incorporation of iron
into the erythroblast.
Previous studies investigating the relation between iron status
and hepcidin showed a positive association between hepcidin and
serum ferritin and liver iron levels [14,15,31]. With the high
prevalence of iron deficiency in these children we would have
expected low hepcidin levels. Although levels were low, the
structural equation model clearly showed that hepcidin was only
weakly associated with bone marrow iron stores. This may be
explained by the influence of the other signaling pathways on
hepcidin production, as erythropoietic and inflammatory path-
ways were strongly associated with hepcidin. In view of these
findings hepcidin was not the preferred marker for iron status
assessment. The soluble transferin receptor-log ferritin index (TfR-
F index) was the more suitable [21], although still not ideal.
Erythropoietin levels were high in these severely anemic
children, and strongly associated with low hepcidin levels. The
regression coefficients determined in the structural equation
model, and occurrence of low hepcidin levels despite a high
incidence of infection, suggested that the down-regulating effect of
erythropoietin exceeded the up-regulating effect of inflammation.
This interpretation is supported by the observation of higher
hepcidin with lower erythropoietin values, and higher CRP and
IL-6 levels in the control group. Erythropoietin dominating
inflammation has also been reported in an infectious murine
model in which low hepcidin values were observed following
administration of erythropoietin [32]. Similar findings were
reported in humans although these subjects had less inflammation
compared to children in the present study [33,34]. It is unclear
whether erythropoietin is directly down regulating hepatic
hepcidin synthesis, or indirectly through induced erythropoiesis
and the previously proposed associated erythropoietic factors, i.e.
growth differentiation factor-15 (GDF15) and twisted gastrulation
protein homolog-1 (TWSG1) [35].
Hypoxia may directly down regulate hepcidin release [36]. It
was therefore expected that hemoglobin and hepcidin concentra-
tions would be positively correlated which was not observed. An
explanation could be that the severity of anemia may have
reduced the heterogeneity of the hepcidin response. As a regulator
of available (utilizable) iron, hepcidin was also expected to be
positively associated with erythroblast iron incorporation. This
association was not observed, which is in contrast with findings in
Gambian children after 14 days of oral iron supplementation [17].
Our findings are consistent with those of Cercamondi et al, who
reported that hepcidin was associated with intestinal iron
absorption, but not with red blood cell iron incorporation [37].
These differences may relate to intermediate factors interfering
with iron incorporation and explain the lack of correlation
between hepcidin and erythroblast iron incorporation in the
present study. Furthermore, iron availability (through absorption
and release from storage), and iron incorporation are dynamic
processes which may be difficult to profile using cross-sectional
data. Inflammatory factors, other than hepcidin, may inhibit
erythroblast iron incorporation as this was not correlated with
hepcidin, malaria, or IL-6, but was significantly associated with
raised CRP values.
Figure 4. Hypothetic model of the iron metabolism in severely anemic children. Severe anemia is associated with severe infections [7]; the
associated high levels of IL-6 induce hepcidin [12]. Although in severe anemia hypoxia stimulates the kidneys to produce erythropoietin; the
erythropoietin induced erythropoietic drive will down-regulate hepatic hepcidin expression, and may overrule hepcidin stimulation of IL-6. The
resulting low hepcidin values are associated with decreased degradation of the cellular iron exporter ferroportin; in iron replete subjects or during
iron supplementation/treatment this will lead to a rise in plasma iron levels [12]. In infection endemic areas this may increase infection risk [5,40]. In
addition inflammatory related factors possibly inhibit erythroblast iron incorporation. CRP: c-reactive protein; ery: erythroblast; epo: erythropoietin;
Fe: plasma iron; FPN: ferroportin; hep: hepcidin-25; IL-6; interleukin 6.
doi:10.1371/journal.pone.0078964.g004
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Considerations and limitations
The majority (57%) of severely anemic children in this study
had hepcidin values ,0.5 nM, which might indicate hepcidin
production was completely ‘‘switched off’’. Analyses were there-
fore repeated with hepcidin as a dichotomous value which showed
comparable outcomes. A more sensitive test with a lower hepcidin
detection limit may provide an improved correlation between
hepcidin and iron status, but this is a general limitation of current
hepcidin assays.
Ideally the fit of the structural equation model, represented by
the root mean square area of approximation (RMSEA), would be
smaller then 0.050. Our RMSEA was 0.288 which may be
explained in part by missing values. Application of this model to a
similar but complete data set should decrease the RMSEA and
provide a stronger hypothetical model. Another explanation for
the high RMSEA approximation could be a missing intermediate
model variable, such as an unmeasured erythropoietic or
inflammatory factor.
It is important to note that variation in bone marrow findings
can result from an uneven distribution of iron in the bone marrow
[20]. Therefore a minimum of 10 bone marrow particles per
aspirate was examined to optimize sensitivity of the bone marrow
examination [38]. Bone marrow assessment is still generally
considered the most reliable diagnostic test for iron status [20].
Clinical implications
These findings raise concerns with respect to iron supplemen-
tation and treatment in severely anemic children living in malaria
endemic areas with high infection pressure. In these severely
anemic children hepcidin concentrations were low, despite
evidence of inflammation in the laboratory findings. With
inflammation a rise in hepcidin would be expected, which would
diminish iron absorption and availability for pathogens, including
malaria parasites [39]. Iron supplementation/treatment , as
currently recommended for severely anemic children [6], could
in enhance infection risk in these children (figure 4). There is a
need for studies investigating iron uptake using stable isotopes in
severely anemic children with malaria, or other infectious diseases,
and to assess infection incidence in children with low hepcidin
levels receiving iron supplementation.
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